Related Experiment Video
Updated: Jun 4, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Molecular diagnostics of lung cancer for treatment stratification]
L C Heukamp1, J Wolf, R Büttner
1Institut für Pathologie, Universitätsklinikum Köln, Köln, Köln. Lukas.heukamp@uk-koeln.de
Abstract:
Lung tumors continue to be the most frequent cause of cancer-related death in Western industrialized countries. The development of new chemotherapeutic substances that are directed specifically against oncogenic pathomechanisms of non-small cell lung cancer represents a promising therapeutic approach. Meanwhile treatment measures are being employed for pulmonary adenocarcinomas that target the epidermal growth factor receptor and transforming EML4-ALK fusion protein. However, these therapies benefit almost exclusively those patients who have never smoked and manifest relatively rare subtypes of adenocarcinomas. In contrast, targeted therapeutic options for squamous cell carcinomas of the lung frequently found in smokers are still limited, although amplifications of the fibroblast growth factor receptor 1 have recently been identified as possible therapeutic targets in this patient population. This contribution provides an overview of the underlying pathomechanisms and molecular diagnostics needed for treatment stratification.
Insights
Lung cancer remains a leading cause of cancer death. While targeted therapies exist for some non-small cell lung cancer subtypes, options for squamous cell carcinomas in smokers are limited, highlighting a need for new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Lung cancer, particularly non-small cell lung cancer (NSCLC), is a major cause of cancer mortality.
- Current targeted therapies for NSCLC, such as those targeting the epidermal growth factor receptor and EML4-ALK fusion protein, are effective only in specific patient subsets (e.g., never-smokers with rare adenocarcinoma subtypes).
- Squamous cell lung carcinoma, prevalent in smokers, has limited targeted treatment options.
Purpose:
- To provide an overview of the pathomechanisms driving lung cancer development.
- To discuss molecular diagnostics essential for stratifying patients for targeted therapies.
- To highlight the need for developing new therapeutic strategies for NSCLC, especially squamous cell carcinoma.
Summary:
- This review examines the molecular underpinnings of lung tumors, focusing on non-small cell lung cancer.
- It contrasts existing targeted therapies for adenocarcinoma with the limited options for squamous cell carcinoma, a common smoking-related lung cancer.
- Recent findings, such as fibroblast growth factor receptor 1 amplifications, offer potential new therapeutic targets for squamous cell carcinoma.
Impact:
- Informs the development of novel, targeted chemotherapeutic agents for lung cancer.
- Facilitates improved treatment stratification through molecular diagnostics.
- Addresses the unmet need for effective therapies in smokers with squamous cell lung carcinoma.